Format

Send to

Choose Destination
Eur Child Adolesc Psychiatry. 2011 Jan;20(1):17-37. doi: 10.1007/s00787-010-0140-6. Epub 2010 Nov 3.

European guidelines on managing adverse effects of medication for ADHD.

Author information

1
Child and Adolescent Psychiatry, The Centre for Child Health, Dundee, UK. JGraham3@nhs.net

Abstract

The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical subspecialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks.

PMID:
21042924
PMCID:
PMC3012210
DOI:
10.1007/s00787-010-0140-6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center